

Osilodrostat prior and new use in patients with endogenous Cushing’s syndrome: 2-year interim analysis results (safety and effectiveness) from the real-world non-interventional LINC 6 study

Nicolas Scheyer,¹ Frédéric Castinetti,² Eliza B Geer,³ Stephanie Espiard,⁴ Celine Mouly,⁵ Laura Dichtel,⁶ Maria Fleseriu,⁷ Antoine Tabarin,⁸ Martin Reincke,⁹ Rosario Pivonello,¹⁰ Richard Feelders,¹¹ Jeannie Le Mouhaër,¹² Peppi Raunioniemi,¹³ Arnd Mueller,¹³ Irina Bancos¹⁴

¹Département d'Endocrinologie, Diabétologie, et Nutrition, CHRU de Nancy, Hôpital Brabois et Université de Lorraine, Vandœuvre-lès-Nancy, France; ²Aix-Marseille University, INSERM, MMG, Department of Endocrinology, La Conception Hospital, Assistance Publique Hôpitaux de Marseille, Marseille, France; ³Multidisciplinary Pituitary and Skull Base Tumor Center, Departments of Medicine and Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴CHU de Lille, Lille, France; ⁵Hôpital Larrey, CHU de Toulouse, Toulouse, France; ⁶Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA; ⁷Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA; ⁸CHU de Bordeaux and Centre de Référence des Maladies Rares de la Surrénale, Bordeaux, France; ⁹Ludwig-Maximilians-Universität München, Munich, Germany; ¹⁰Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy; ¹¹Department of Internal Medicine, Endocrine Section, Erasmus Medical Center, Rotterdam, Netherlands; ¹²Recordati Rare Diseases SARL, Paris, France; ¹³Recordati AG, Basel, Switzerland; ¹⁴Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA



Please scan this quick response (QR) code with your smartphone camera or app to obtain a copy of this poster.
Alternatively, please visit the link: <https://qramiculum.biz/cu5yc4/>
Copies of this poster obtained through the QR code are for personal use only and may not be reproduced without permission from ESPE, ESE and the authors of this poster.

INTRODUCTION

- Endogenous Cushing's syndrome often requires lifelong medical treatment; further long-term data are therefore needed for all aetiologies, including non-pituitary forms, of Cushing's syndrome
- Osilodrostat is a potent 11 β -hydroxylase inhibitor that provides rapid and sustained suppression of cortisol and improves clinical signs and symptoms of hypercortisolism and quality-of-life outcomes in patients with Cushing's syndrome
 - Long-term safety and efficacy of osilodrostat were shown in the LINC clinical trial programme in patients with Cushing's disease (Phase II: LINC 2, NCT01331239; Phase III: LINC 3, NCT02180217 and LINC 4, NCT02697734)¹⁻⁵
 - Osilodrostat efficacy and safety were also evaluated in a Phase II study in Japanese patients with non-pituitary forms of Cushing's syndrome⁶
- The LINC 6 study further evaluates the long-term safety and effectiveness of osilodrostat in patients with endogenous Cushing's syndrome during 3 years of routine clinical practice; data from the prespecified 2-year interim analysis are reported here

METHODS

- The ongoing prospective, non-interventional, multinational LINC 6 (NCT05382156) study enrolled the first adult patient with endogenous Cushing's syndrome on 13 June 2022, and will follow individual patients for up to 3 years
- Patients were enrolled across 40 sites in France, Germany, Italy, the Netherlands and the USA where osilodrostat is approved and available
 - Patients could have received prior osilodrostat treatment either as a monotherapy or in combination with another treatment for hypercortisolism
 - Patients were usually treated according to local prescribing information at the treating physician's discretion
 - Patients could not receive another investigational drug in another clinical trial
 - Patients who were treated with osilodrostat and consented to data collection were enrolled consecutively
- The primary endpoint is the incidence of osilodrostat-related AEs and SAEs, with a focus on AEs related to hypocortisolism, accumulation of adrenal hormone precursors, QT prolongation and pituitary tumour enlargement
- Key secondary endpoints include normalisation of mUFC, LNSC and serum cortisol levels among patients with assessments at baseline and month 6
- AEs were recorded at each patient visit
- Outcomes were assessed separately in new (those starting osilodrostat at or after study entry) and prior osilodrostat users (those starting osilodrostat any time before study entry) at the prespecified 2-year interim cut-off (24 July 2024); all assessments are descriptive

RESULTS

Baseline characteristics

- Overall, 206 patients were included in the safety population (received ≥ 1 osilodrostat dose); osilodrostat treatment status at enrolment was available for 205 patients
- Of the 205 patients evaluated, 70 were new and 135 were prior osilodrostat users
- Patient characteristics were typical of a population with Cushing's syndrome and were mostly similar between new and prior osilodrostat users; however, a greater proportion of prior users had Cushing's disease
- Baseline mUFC was just above the ULN in prior users but substantially higher in new osilodrostat users

Country N (%)	France 84 (41.0)	USA 81 (39.5)	Germany 27 (13.2)	Italy 8 (3.9)	Netherlands 5 (2.4)
New osilodrostat users: n (%)	32 (45.7)	16 (22.9)	12 (17.1)	5 (7.1)	5 (7.1)
Prior osilodrostat users: n (%)	52 (38.5)	65 (48.1)	15 (11.1)	3 (2.2)	0


Patient characteristics	New osilodrostat users (n=70)	Prior osilodrostat users (n=135)
Mean (SD) age, years	50.8 (15.1)	54.1 (13.9)
Female, n (%)	55 (78.6)	100 (74.1)
Mean (SD) weight, kg	84.1 (18.6)	84.7 (26.8)
Mean (SD) BMI, kg/m ²	30.8 (6.9)	30.8 (9.9)
Cushing's disease, n (%)	49 (70.0)	112 (83.0)

Non-pituitary Cushing's syndrome, n (%)	21 (30.0)	23 (17.0)
Ectopic	4 (5.7)	13 (9.6)
Adrenal adenoma	9 (12.9)	3 (2.2)
BND	5 (7.1)	5 (3.7)
Adrenal carcinoma	2 (2.9)	0
Other*	1 (1.4)	2 (1.5)


Patients with prior surgery, n (%)	25 (59.5)*	86 (63.7)
Mean (SD) mUFC, mmol/24 h	587.5 (723.6)	148.9 (152.1)

*Other refers to primary pigmented nodular adrenocortical disease (n=1) in new users and micronodular adrenal dysplasia and unknown (n=1) in prior users; *Data were available for only 42 patients

Osilodrostat dose and exposure




1. The proportions of patients experiencing an AE were similar among new and prior users; AEs related to osilodrostat were slightly more frequent in prior users



- Most treatment-related AEs were mild or moderate in both new (93.3%) and prior (94.7%) osilodrostat users
- AEs led to death in two new (2.9%, n=2/70; adrenal insufficiency, adrenocortical carcinoma and lung disorder) and three prior osilodrostat users (2.2%, n=3/135; haemolysis, hypovolemic shock after probable adrenal insufficiency, sepsis and respiratory distress)

2. AEs related to hypocortisolism or accumulation of adrenal hormone precursors were infrequent and manageable without discontinuation in most patients




Reported as (events): *Adrenal insufficiency (new=6; prior=16), acute adrenocortical insufficiency (new=2; prior=4) and glucocorticoid deficiency (new=1; prior=1); *Peripheral oedema (new=2; prior=3), hypokalaemia (new=2; prior=2), abnormal hair growth (new=3; prior=0), acne (new=2; prior=1), hirsutism (new=1; prior=2), hyperandrogenism (new=0; prior=2) and hypertension (new=0; prior=2); *ACTH-producing pituitary tumour (new=1; prior=0), pituitary tumour (new=0; prior=1) and benign pituitary tumour (new=0; prior=1); *Loss of consciousness (new=1; prior=0) and syncope (new=1; prior=1)

- Few AEs related to hypocortisolism (new user, 11.1% of events [n=1/9]; prior user, 9.5% of events [n=2/21]) or accumulation of adrenal hormone precursors (new user, 0% of events; prior user, 16.7% of events [n=2/12]) led to discontinuation of osilodrostat
- Similar proportions of patients or events in each group required glucocorticoid supplementation for hypocortisolism or corrective therapy for accumulation of adrenal hormone precursors

CONCLUSIONS


- At the prespecified 2-year interim analysis cut-off, the safety profile of osilodrostat in patients with endogenous Cushing's syndrome was as expected and consistent with previous studies²⁻⁵
 - AEs related to osilodrostat were slightly more frequent in prior than in new osilodrostat users; no new safety signals were identified
 - The most common AE in new and prior osilodrostat users was adrenal insufficiency
 - AEs related to hypocortisolism occurred at similar frequencies in new and prior osilodrostat users; few led to permanent osilodrostat discontinuation
 - AEs related to accumulation of adrenal hormone precursors were more frequent in new versus prior users; however, none of these AEs led to osilodrostat discontinuation among new users
 - SAEs were more common in new than in prior osilodrostat users
 - Most AEs were mild or moderate in severity and manageable with corrective therapy
- Rates of mUFC and LNSC normalisation increased in new users from baseline to month 6 and were maintained in most prior users
- These LINC 6 interim data show the real-world clinical utility of osilodrostat for the management of endogenous Cushing's syndrome in new and prior users with differing aetiologies

3. SAEs occurred at a higher frequency in new than in prior osilodrostat users



New users also reported acute adrenocortical insufficiency, hyperadrenocorticism, intestinal diverticulitis perforation, asthenia, pyrexia, haematoma infection, acute pyelonephritis, dehydration, hyperkalaemia, ACTH-producing pituitary tumour, adrenocortical carcinoma, breast cancer, loss of consciousness, acute pulmonary oedema and lung disorder (all n=1/24; 4.2% each); prior users reported haemolysis, adrenal insufficiency, death, disease progression, infection, bacterial pneumonia, viral pneumonia, sepsis, septic shock, hyperkalaemia, glioblastoma, pituitary tumour, benign pituitary tumour, altered state of consciousness, acute kidney injury, asthma and respiratory distress (all n=1/21; 4.8% each)


4. Most AEs were managed by corrective therapy,* dose adjustments or interruption



*Includes concomitant medication (including glucocorticoids), surgery and other (blood transfusion, blood letting, scans, antibiotics or catecholamines, percutaneous drain placement, intravenous fluids, total parenteral nutrition, parenteral hydration, nasogastric tube, ventilation, urinary catheter, emergency room visit outside of hospital); *New users also reported adrenal insufficiency, hyperadrenocorticism, adrenal gland cancer, adrenocortical carcinoma, pregnancy and acute pulmonary oedema (all n=1/6; 16.7% each); prior users reported adrenal insufficiency (n=2/11; 18.2%), hyperandrogenism, nausea, vomiting, disease progression, sepsis, abnormal hormone level, benign pituitary tumour, dizziness, pregnancy, adrenalectomy, inadequately controlled blood pressure, hypertension and orthostatic hypotension (all n=1/11; 9.1% each)

- One new (1.4%, n=1/70) and six prior (4.4%, n=6/135) users discontinued because of 11 AEs (new, n=1; prior, n=10) considered treatment related

5. Rates of mUFC and LNSC normalisation increased from baseline to month 6 in new users and were maintained in most prior users



Normal values were defined by each centre. Serum cortisol levels were assessed according to standard clinical practice at each site, but this was not mandated by the study protocol. At the prespecified 2-year interim analysis cut-off, not all patients had their 6-month visit; therefore, patient numbers were small for some analyses

ACKNOWLEDGEMENTS

We thank Lyssa Gold, of AMICULUM Business Services Limited (funded by Recordati AG), for providing medical editorial assistance, as well as the site investigators, study coordinators/nurses and patients who are participating in the study.

ABBREVIATIONS

ACTH, adrenocorticotrophic hormone; AE, adverse event; BMI, body mass index; BND, bilateral adrenal nodular disease; LNSC, late-night salivary cortisol; mUFC, mean urinary free cortisol; SAE, serious adverse event; SD, standard deviation; ULN, upper limit of normal

DISCLOSURES

The LINC 6 study is funded by Recordati Rare Diseases.

REFERENCES

- Fleseriu M *et al. Pituitary* 2022;25:959–70
- Pivonello R *et al. Lancet Diabetes Endocrinol* 2020;8:748–61
- Fleseriu M *et al. Eur J Endocrinol* 2022;187:531–41
- Gadelha M *et al. Front Endocrinol (Lausanne)* 2023;14:1236465
- Gadelha M *et al. J Clin Endocrinol Metab* 2022;107:e2882–95
- Tanaka T *et al. Endocr J* 2020;67:841–52